Gliflozin as a key oral hypoglycaemic agent to control type 2 diabetes in a patient with a history of ischaemic heart disease and heart failure
2021
Abstract
Gliflozins are well known oral hypoglycaemic agents, which were recently approved also for heart failure and renal insufficiency treatment. This case report describes a traditional scenario where gliflozin is the rational choice of therapy in a patient with uncontrolled diabetes and a history of ischaemic heart disease with heart failure, leading to early improvement of diabetes control and also long-term reduction of cardiovascular risk in a high-risk polymorbid patient.